Refining Early Antitumoral Drug Development
2018
The failure rate of development of new drugs in oncology is high, with up to 95% of drugs tested in Phase I not reaching the market. Causes behind this high failure rate are discussed here, and solutions to increase the success in the development of antitumor drugs are suggested.
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
19
References
9
Citations
NaN
KQI